NEW YORK – Prometheus Biosciences announced on Friday that it has priced its upsized initial public offering of 10 million shares of common stock at $19 per share.
The shares are expected to start trading on the Nasdaq on March 12 under ticker symbol RXDX. Prometheus expects gross proceeds from the offering, expected to close on March 16, to be $190 million.